DanCann Pharma A/S (NGM:DANCAN)

DanCann Pharma Statistics

Total Valuation

DanCann Pharma has a market cap or net worth of SEK 4.68 million. The enterprise value is 4.73 million.

Market Cap	4.68M
Enterprise Value	4.73M

Important Dates

The last earnings date was Monday, August 25, 2025.

Earnings Date	Aug 25, 2025
Ex-Dividend Date	n/a

Share Statistics

DanCann Pharma has 3.99 million shares outstanding. The number of shares has decreased by -95.22% in one year.

Current Share Class	3.99M
Shares Outstanding	3.99M
Shares Change (YoY)	-95.22%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	3.28%
Float	3.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.74
PB Ratio	0.36
P/TBV Ratio	4.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.28
EV / Sales	0.76
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.47

Current Ratio	0.47
Quick Ratio	0.25
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-15.58

Financial Efficiency

Return on equity (ROE) is -149.15% and return on invested capital (ROIC) is -79.99%.

Return on Equity (ROE)	-149.15%
Return on Assets (ROA)	-35.67%
Return on Invested Capital (ROIC)	-79.99%
Return on Capital Employed (ROCE)	-110.28%
Revenue Per Employee	1.27M
Profits Per Employee	-3.38M
Employee Count	5
Asset Turnover	0.25
Inventory Turnover	21.54

Taxes

In the past 12 months, DanCann Pharma has paid 1.65 million in taxes.

Income Tax	1.65M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -88.54% in the last 52 weeks. The beta is 1.99, so DanCann Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.99
52-Week Price Change	-88.54%
50-Day Moving Average	0.96
200-Day Moving Average	1.94
Relative Strength Index (RSI)	40.36
Average Volume (20 Days)	33,224

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, DanCann Pharma had revenue of SEK 6.36 million and -16.88 million in losses. Loss per share was -4.23.

Revenue	6.36M
Gross Profit	-4.46M
Operating Income	-14.48M
Pretax Income	-15.23M
Net Income	-16.88M
EBITDA	-11.46M
EBIT	-14.48M
Loss Per Share	-4.23

Balance Sheet

The company has -56,889 in cash and n/a in debt, giving a net cash position of -56,889 or -0.01 per share.

Cash & Cash Equivalents	-56,889
Total Debt	n/a
Net Cash	-56,889
Net Cash Per Share	-0.01
Equity (Book Value)	13.13M
Book Value Per Share	3.29
Working Capital	-3.64M

Cash Flow

Operating Cash Flow	-7.02M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is -70.08%, with operating and profit margins of -227.75% and -265.42%.

Gross Margin	-70.08%
Operating Margin	-227.75%
Pretax Margin	-239.43%
Profit Margin	-265.42%
EBITDA Margin	-180.27%
EBIT Margin	-227.75%
FCF Margin	n/a

Dividends & Yields

DanCann Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	95.22%
Shareholder Yield	n/a
Earnings Yield	-360.86%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 24, 2025. It was a reverse split with a ratio of 0.001.

Last Split Date	Feb 24, 2025
Split Type	Reverse
Split Ratio	0.001

Scores

DanCann Pharma has an Altman Z-Score of -0.71 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.71
Piotroski F-Score	2